Findings

What do systematic reviews say?

1,340 questions · 1,512 findings · 205 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 317 · 21%GRADE not reported 358 · 23.7%Very low 356 · 23.5%Low 271 · 17.9%Moderate 173 · 11.4%High 37 · 2.4%

Pathogen‐reduced platelets vs standard platelets

Number of platelet transfusions per participant up to 30 days from study entry · thrombocytopenia

1 finding from 1 review

Pathogen‐reduced platelets for the prevention of bleeding 2017 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 1509 participants
High

HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZUCLOPENTHIXOL ACETATE

Tranquillisation or asleep ‐ not reported · patients with psychosis‐induced aggression or agitation

The review found no eligible studies for this question.

1 finding from 1 review

Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZUCLOPENTHIXOL ACETATE

Repeated need for rapid tranquillisation ‐ more than 3 injections · patients with psychosis‐induced aggression or agitation

It is very uncertain whether HALOPERIDOL changes repeated need for rapid tranquillisation ‐ more than 3 injections compared with OTHER ANTIPSYCHOTIC: k. ZUCLOPENTHIXOL ACETATE (very low certainty).

1 finding from 1 review

Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) 2017 · Cochrane Headline outcomes only
RR 2.54 [1.19, 5.46]
1 study · 70 participants
Very low

HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZUCLOPENTHIXOL ACETATE

Specific behaviour ‐ threat or injury to self or others ‐ not reported · patients with psychosis‐induced aggression or agitation

The review found no eligible studies for this question.

1 finding from 1 review

Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZUCLOPENTHIXOL ACETATE

Global outcome ‐ not reported · patients with psychosis‐induced aggression or agitation

The review found no eligible studies for this question.

1 finding from 1 review

Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZUCLOPENTHIXOL ACETATE

Tremor · patients with psychosis‐induced aggression or agitation

It is very uncertain whether HALOPERIDOL changes adverse effects: specific ‐ tremor by 7 days compared with OTHER ANTIPSYCHOTIC: k. ZUCLOPENTHIXOL ACETATE (very low certainty).

1 finding from 1 review

Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) 2017 · Cochrane Headline outcomes only
RR 4.16 [0.93, 18.62]
1 study · 70 participants
Very low

HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZUCLOPENTHIXOL ACETATE

Economic outcome ‐ not reported · patients with psychosis‐induced aggression or agitation

The review found no eligible studies for this question.

1 finding from 1 review

Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Thrombopoietin mimetics vs placebo

Overall survival · Adult patients with myelodysplastic syndromes and thrombocytopenia

1 finding from 1 review

Thrombopoietin mimetics for patients with myelodysplastic syndromes 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 282 participants
GRADE not reported

Thrombopoietin mimetics vs placebo

Mortality during study · Adult patients with myelodysplastic syndromes and thrombocytopenia

Thrombopoietin mimetics showed no clear difference in mortality during study compared with placebo (low certainty).

1 finding from 1 review

Thrombopoietin mimetics for patients with myelodysplastic syndromes 2017 · Cochrane Headline outcomes only
RR 0.97 [0.73, 1.27]
6 studies · 746 participants
Low

Thrombopoietin mimetics vs placebo

Transformation to AML · Adult patients with myelodysplastic syndromes and thrombocytopenia

It is very uncertain whether thrombopoietin mimetics changes transformation to AML compared with placebo (very low certainty).

1 finding from 1 review

Thrombopoietin mimetics for patients with myelodysplastic syndromes 2017 · Cochrane Headline outcomes only
RR 1.02 [0.59, 1.77]
5 studies · 372 participants
Very low

Thrombopoietin mimetics vs placebo

Incidence of bleeding events · Adult patients with myelodysplastic syndromes and thrombocytopenia

Thrombopoietin mimetics probably leads to lower incidence of bleeding events compared with placebo (moderate certainty).

1 finding from 1 review

Thrombopoietin mimetics for patients with myelodysplastic syndromes 2017 · Cochrane Headline outcomes only
RR 0.92 [0.86, 0.98]
5 studies · 390 participants
Moderate

Thrombopoietin mimetics vs placebo

Blood transfusion requirements · Adult patients with myelodysplastic syndromes and thrombocytopenia

Thrombopoietin mimetics showed no clear difference in transfusion requirement compared with placebo (low certainty).

1 finding from 1 review

Thrombopoietin mimetics for patients with myelodysplastic syndromes 2017 · Cochrane Headline outcomes only
RR 0.83 [0.66, 1.05]
4 studies · 358 participants
Low

Thrombopoietin mimetics vs placebo

Health‐related quality of life · Adult patients with myelodysplastic syndromes and thrombocytopenia

The review found no eligible studies for this question.

1 finding from 1 review

Thrombopoietin mimetics for patients with myelodysplastic syndromes 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Thrombopoietin mimetics vs placebo

All adverse events · Adult patients with myelodysplastic syndromes and thrombocytopenia

Thrombopoietin mimetics showed no clear difference in all adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Thrombopoietin mimetics for patients with myelodysplastic syndromes 2017 · Cochrane Headline outcomes only
RR 1.01 [0.96, 1.07]
5 studies · 390 participants
Moderate

Thrombopoietin mimetics vs placebo

Serious adverse events · Adult patients with myelodysplastic syndromes and thrombocytopenia

It is very uncertain whether thrombopoietin mimetics changes serious adverse events compared with placebo (very low certainty).

1 finding from 1 review

Thrombopoietin mimetics for patients with myelodysplastic syndromes 2017 · Cochrane Headline outcomes only
RR 0.89 [0.54, 1.46]
4 studies · 356 participants
Very low

Intramedullary fixation vs open reduction and internal fixation with plate

Function (overall) Various tools · adults (aged ≥ 16 years) with acute middle third clavicle fractures

Intramedullary fixation may leads to higher function or disability (overall) Various tools (Constant score and… compared with open reduction and internal fixation with plate (low certainty).

1 finding from 1 review

Surgical interventions for treating acute fractures or non‐union of the middle third of the clavicle 2015 · Cochrane Headline outcomes only
SMD 0.45 [0.08, 0.81]
3 studies · 120 participants
Low

Intramedullary fixation vs open reduction and internal fixation with plate

Pain ‐ using the section of Constant score Scale from 0 to 15; with 15 being the best positive score · adults (aged ≥ 16 years) with acute middle third clavicle fractures

It is very uncertain whether intramedullary fixation changes pain ‐ using the section of Constant score Scale from 0 to 15; with… compared with open reduction and internal fixation with plate (very low certainty).

1 finding from 1 review

Surgical interventions for treating acute fractures or non‐union of the middle third of the clavicle 2015 · Cochrane Headline outcomes only
MD 0.6
1 study · 32 participants
Very low

Intramedullary fixation vs open reduction and internal fixation with plate

Treatment failure (participants who have a non‐routine secondary surgical intervention) ‐ Overall treatment failure · adults (aged ≥ 16 years) with acute middle third clavicle fractures

It is very uncertain whether intramedullary fixation changes treatment failure (participants who have a non‐routine secondary… compared with open reduction and internal fixation with plate (very low certainty).

1 finding from 1 review

Surgical interventions for treating acute fractures or non‐union of the middle third of the clavicle 2015 · Cochrane Headline outcomes only
RR 0.69 [0.16, 2.97]
4 studies · 133 participants
Very low

Intramedullary fixation vs open reduction and internal fixation with plate

Clinical healing ‐ time to clinical/radiographic fracture consolidation (weeks) · adults (aged ≥ 16 years) with acute middle third clavicle fractures

It is very uncertain whether intramedullary fixation changes clinical healing ‐ time to clinical/radiographic fracture… compared with open reduction and internal fixation with plate (very low certainty).

1 finding from 1 review

Surgical interventions for treating acute fractures or non‐union of the middle third of the clavicle 2015 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 98 participants
Very low

Intramedullary fixation vs open reduction and internal fixation with plate

Adverse events ‐ total of adverse events (various: mainly infection; cosmetic result ‐ e.g. prominent metalwork ‐ and symptomatic hardware) · adults (aged ≥ 16 years) with acute middle third clavicle fractures

It is very uncertain whether intramedullary fixation changes adverse events ‐ total of adverse events (various: mainly infection;… compared with open reduction and internal fixation with plate (very low certainty).

1 finding from 1 review

Surgical interventions for treating acute fractures or non‐union of the middle third of the clavicle 2015 · Cochrane Headline outcomes only
RR 0.64 [0.39, 1.03]
4 studies · 133 participants
Very low